References
- Gupta AK, Batra R, Bluhm R, et al. Pityriasis versicolor. Dermatol Clin. 2003;21:413–29
- Odom RB, James WD, Berger TG, eds. Diseases resulting from fungi and yeasts. In: Andrews' Diseases of the Skin. 9th ed. Philadelphia: WB Saunders, 2000. p 358–416
- Borelli D, Jacobs PH, Nall L. Tinea versicolor: epidemiologic, clinical and therapeutics aspects. J Am Acad Dermatol. 1991;25:300–5
- Elewski BE. Cutaneous mycoses in children. Br J Dermatol. 1996;134(Suppl. 46):7–11
- Yazdanpanah MJ, Azizi H, Suizi B. Comparison between fluconazole and ketoconazole effectivity in the treatment of pityriasis versicolor. Mycoses. 2007;50:311–13
- Rigopoulos D, Gregoriou S, Kontochristopoulos G, et al. Flutrimazole shampoo 1% versus ketoconazole shampoo 2% in the treatment of pityriasis versicolor. A randomised double-blind comparative trial. Mycoses. 2007;50:193–5
- Wroblewska MM, Swoboda-Kopec E, Rokosz A, et al. Epidermiology of clinical isolates of Candida albicans and their susceptibility to triazoles. Int J Antimicrob Agents. 2002;20:472–5
- Snelders E, vander Lee HA, Kuijpers J, et al. Emergence of azole resistance in Aspergillus fumigatus and spread of a single resistance mechanism. PLoS Med. 2008;5:219
- Verschoore M, Poncet M, Czernielewski J, et al. Adapalene 0.1% gel has low skin-irritation potential. J Am Acad Dermatol. 1997;36:S104–9
- Brand B, Gilbert R, Baker MD, et al. Cumulative irritancy comparison of adapalene gel 0.1% versus other retinoid products when applied in combination with topical antimicrobial agents. J Am Acad Dermatol. 2003;49(Suppl. 3):S227–32
- Shi TW, Ren XK, Yu HX, et al. Roles of adapalene in the treatment of pityriasis versicolor. Dermatology. 2012;224:184–8